{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:22:54Z","timestamp":1791901374770,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1093\/annonc\/mdm508","type":"journal-article","created":{"date-parts":[[2007,11,17]],"date-time":"2007-11-17T02:10:19Z","timestamp":1195265419000},"page":"577-582","source":"Crossref","is-referenced-by-count":166,"title":["Management of bevacizumab-associated bowel perforation: a case series and review of the literature"],"prefix":"10.1016","volume":"19","author":[{"given":"B.D.","family":"Badgwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.R.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Feig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.N.","family":"Cormier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1093\/annonc\/mdm508_bb0010","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1093\/annonc\/mdm508_bb0015","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1093\/annonc\/mdm508_bb0020","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1093\/annonc\/mdm508_bb0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1093\/annonc\/mdm508_bb0030","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdm508_bb0035","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1093\/annonc\/mdm508_bb0040","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2005.01.9661","article-title":"Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer","volume":"23","author":"Kindler","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdm508_bb0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000088483","article-title":"Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer","volume":"69","author":"de Gramont","year":"2005","journal-title":"Oncology"},{"issue":"4935","key":"10.1093\/annonc\/mdm508_bb0050","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"issue":"4935","key":"10.1093\/annonc\/mdm508_bb0055","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdm508_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology"},{"issue":"5","key":"10.1093\/annonc\/mdm508_bb0065","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18 Suppl","key":"10.1093\/annonc\/mdm508_bb0070","article-title":"Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [meeting abstracts]","volume":"24","author":"Hedrick","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdm508_bb0075","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18 Suppl","key":"10.1093\/annonc\/mdm508_bb0080","article-title":"Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy [meeting abstracts]","volume":"24","author":"Sugrue","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdm508_bb0085","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","article-title":"2001 SCCM\/ESICM\/ACCP\/ATS\/SIS International Sepsis Definitions Conference","volume":"31","author":"Levy","year":"2003","journal-title":"Crit Care Med"},{"issue":"21","key":"10.1093\/annonc\/mdm508_bb0090","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2005.05.1573","article-title":"Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdm508_bb0095","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","article-title":"Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer","volume":"24","author":"Crane","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdm508_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21969","article-title":"Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis","volume":"107","author":"Wright","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm508_bb0105","unstructured":"Genentech Press-Release from 9\/23\/05 http:\/\/www.gene.com\/gene\/news\/press-releases\/index.jsp2 January 2007, date last accessed)"},{"issue":"7","key":"10.1093\/annonc\/mdm508_bb0110","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1097\/00003246-200007000-00078","article-title":"Pneumoperitoneum: a review of nonsurgical causes","volume":"28","author":"Mularski","year":"2000","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1093\/annonc\/mdm508_bb0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdm508_bb0120","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cursur.2006.06.002","article-title":"Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management","volume":"63","author":"Heinzerling","year":"2006","journal-title":"Curr Surg"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/3\/577\/683869\/mdm508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:55:59Z","timestamp":1624442159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419411769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0923753419411769"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm508","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}